Sales of Acomplia….
Sunday, February 17th, 2008With sales of Acomplia (rimonabant) lagging in the several dozen countries where it is on the market, Sanofi-Aventis executives had little to say about their pioneering obesity treatment in a report to analysts on Feb. 12th. But that hardly means they have given up on the CB-1 receptor antagonist.
Instead, Sanofi unveiled plans to make at least three presentations at major U.S. and European medical meetings during 2008 on the results of clinical trials of Acomplia as a treatment for heart disease and diabetes.